It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
It is well established that antibiotic treatment selects for resistance, but the dynamics of this process during infections are poorly understood. Here we map the responses of Pseudomonas aeruginosa to treatment in high definition during a lung infection of a single ICU patient. Host immunity and antibiotic therapy with meropenem suppressed P. aeruginosa, but a second wave of infection emerged due to the growth of oprD and wbpM meropenem resistant mutants that evolved in situ. Selection then led to a loss of resistance by decreasing the prevalence of low fitness oprD mutants, increasing the frequency of high fitness mutants lacking the MexAB-OprM efflux pump, and decreasing the copy number of a multidrug resistance plasmid. Ultimately, host immunity suppressed wbpM mutants with high meropenem resistance and fitness. Our study highlights how natural selection and host immunity interact to drive both the rapid rise, and fall, of resistance during infection.
Here, following a patient with severe acute Pseudomonas aeruginosa infection, the authors combine comprehensive isolate characterization from lung and gut samples (>100 isolates) and patient clinical data to provide insights into bacterial responses to antibiotic therapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Diaz Caballero Julio 1 ; Kapel Natalia 1 ; de Winter Fien H R 2
; Jangir Pramod 1 ; Quinn, Angus 1
; del Barrio-Tofiño Ester 3 ; López-Causapé, Carla 3 ; Hedge, Jessica 1
; Torrens, Gabriel 3 ; Van der Schalk Thomas 2
; Britto, Xavier Basil 2
; Fernández-Cuenca, Felipe 4 ; Arenzana Angel 4 ; Recanatini Claudia 5
; Timbermont Leen 2
; Sifakis Frangiscos 6 ; Ruzin Alexey 7 ; Ali, Omar 8 ; Lammens, Christine 2 ; Goossens, Herman 2 ; Kluytmans Jan 9 ; Kumar-Singh, Samir 10 ; Oliver, Antonio 3 ; Malhotra-Kumar Surbhi 2
; MacLean, Craig 1
1 University of Oxford, Department of Zoology, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
2 Vaccine and Infectious Disease Institute, University of Antwerp, Laboratory of Medical Microbiology, Wilrijk, Belgium (GRID:grid.5284.b) (ISNI:0000 0001 0790 3681)
3 Hospital Universitario Son Espases, Palma de Mallorca, Spain (GRID:grid.411164.7) (ISNI:0000 0004 1796 5984)
4 Universidad de Sevilla, Departamento de Medicina, Seville, Spain (GRID:grid.9224.d) (ISNI:0000 0001 2168 1229)
5 University Medical Center Utrecht, Utrecht University, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
6 Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, USA (GRID:grid.418412.a) (ISNI:0000 0001 1312 9717)
7 Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA (GRID:grid.418152.b)
8 Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, USA (GRID:grid.418152.b); Viela Bio, Gaithersburg, USA (GRID:grid.418152.b)
9 University Medical Center Utrecht, Utrecht University, Julius Center for Health Sciences and Primary Care, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352); Microvida Laboratory for Medical Microbiology and Department of Infection Control, Amphia Hospital, Breda, The Netherlands (GRID:grid.413711.1)
10 Vaccine and Infectious Disease Institute, University of Antwerp, Laboratory of Medical Microbiology, Wilrijk, Belgium (GRID:grid.5284.b) (ISNI:0000 0001 0790 3681); University of Antwerp, Molecular Pathology Group, Faculty of Medicine—Laboratory of Cell Biology and Histology, Wilrijk, Belgium (GRID:grid.5284.b) (ISNI:0000 0001 0790 3681)




